Last reviewed · How we verify
Placebo to match deucravacitinib
Placebo to match deucravacitinib is a TYK2 inhibitor Small molecule drug developed by Takeda. It is currently in Phase 3 development for Moderate to severe plaque psoriasis, Psoriatic arthritis.
Deucravacitinib is a small molecule that acts as a selective tyrosine kinase 2 (TYK2) inhibitor.
Deucravacitinib is a small molecule that acts as a selective tyrosine kinase 2 (TYK2) inhibitor. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis.
At a glance
| Generic name | Placebo to match deucravacitinib |
|---|---|
| Sponsor | Takeda |
| Drug class | TYK2 inhibitor |
| Target | TYK2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
TYK2 is a non-receptor tyrosine kinase involved in the signaling of various cytokines. By inhibiting TYK2, deucravacitinib reduces the activity of these cytokines, leading to anti-inflammatory effects.
Approved indications
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
- Muscle spasms
Key clinical trials
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) (PHASE3)
- A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis (PHASE3)
- A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- Deucravacitinib Rosacea (PHASE2)
- Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match deucravacitinib CI brief — competitive landscape report
- Placebo to match deucravacitinib updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about Placebo to match deucravacitinib
What is Placebo to match deucravacitinib?
How does Placebo to match deucravacitinib work?
What is Placebo to match deucravacitinib used for?
Who makes Placebo to match deucravacitinib?
What drug class is Placebo to match deucravacitinib in?
What development phase is Placebo to match deucravacitinib in?
What are the side effects of Placebo to match deucravacitinib?
What does Placebo to match deucravacitinib target?
Related
- Drug class: All TYK2 inhibitor drugs
- Target: All drugs targeting TYK2
- Manufacturer: Takeda — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Moderate to severe plaque psoriasis
- Indication: Drugs for Psoriatic arthritis
- Compare: Placebo to match deucravacitinib vs similar drugs
- Pricing: Placebo to match deucravacitinib cost, discount & access